The Sidney Kimmel Comprehensive Cancer Center
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Employees
- -
- Market Cap
- -
Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.
Phase 1
Completed
- Conditions
- Pancreatic Ductal AdenocarcinomaLocally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)
- Interventions
- Radiation: Stereotactic Body Radiation (SBRT)Drug: CCR2/CCR5 dual antagonist
- First Posted Date
- 2018-12-06
- Last Posted Date
- 2024-12-10
- Target Recruit Count
- 46
- Registration Number
- NCT03767582
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
Perspectives on Bone Marrow Donors Who Donate for Their Parent
Completed
- Conditions
- Bone Marrow Transplant
- Interventions
- Other: Semi-structured Interview
- First Posted Date
- 2018-11-29
- Last Posted Date
- 2018-11-30
- Target Recruit Count
- 16
- Registration Number
- NCT03758911
Post-Operative Outcomes of Low Thermal Dissection vs. Traditional Electrosurgery
Not Applicable
Completed
- Conditions
- HemostasisBreast CancerMastectomyPerfusion; Complications
- Interventions
- Device: PlasmaBlade 3.0S
- First Posted Date
- 2018-10-19
- Last Posted Date
- 2019-06-18
- Target Recruit Count
- 20
- Registration Number
- NCT03711916
- Locations
- 🇺🇸
Bayview Medical Center, Baltimore, Maryland, United States
🇺🇸Johns Hopkins Hospital Outpatient Center, Baltimore, Maryland, United States
Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer
Phase 1
Active, not recruiting
- Conditions
- Colon CancerUnresectable or Metastatic Microsatellite Stable (MSS) Solid Tumor Along With Microsatellite Stable (MSS) Colon Cancer
- Interventions
- First Posted Date
- 2018-10-18
- Last Posted Date
- 2025-01-13
- Target Recruit Count
- 48
- Registration Number
- NCT03711058
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
A Pilot Trial of Scrambler Therapy for Pain Associated With Pancreas Cancer
Withdrawn
- Conditions
- Cancer PancreasCancer Related PainPain Syndrome
- Interventions
- Device: Scrambler Therapy Device
- Locations
- 🇺🇸
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma
Phase 1
Terminated
- Conditions
- Glioblastoma MultiformeGlioblastoma
- Interventions
- Drug: Anti-GITR Monoclonal Antibody MK-4166Drug: IDO1 inhibitor INCB024360
- First Posted Date
- 2018-10-16
- Last Posted Date
- 2020-07-02
- Target Recruit Count
- 3
- Registration Number
- NCT03707457
- Locations
- 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer
Phase 2
Completed
- Conditions
- Microsatellite Stable (MSS) Colorectal AdenocarcinomasColorectal Adenocarcinoma
- Interventions
- First Posted Date
- 2018-08-22
- Last Posted Date
- 2025-01-28
- Target Recruit Count
- 59
- Registration Number
- NCT03642067
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab
Phase 2
Active, not recruiting
- Conditions
- Intermediate Stage of Hepatocellular CarcinomaHepatocellular Carcinoma
- Interventions
- First Posted Date
- 2018-08-20
- Last Posted Date
- 2023-12-05
- Target Recruit Count
- 30
- Registration Number
- NCT03638141
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
Assessment of Multi-Modality Quantitative Imaging for Evaluation of Response of Metastatic Prostate Cancer to Therapy
Phase 1
Terminated
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2018-08-08
- Last Posted Date
- 2023-10-31
- Target Recruit Count
- 3
- Registration Number
- NCT03619655
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸Thomas Jefferson University, Philadelphia, Pennsylvania, United States
REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer
Phase 1
Active, not recruiting
- Conditions
- Immune Checkpoint InhibitionGastroesophageal Cancer
- Interventions
- First Posted Date
- 2018-08-01
- Last Posted Date
- 2024-12-11
- Target Recruit Count
- 21
- Registration Number
- NCT03610711
- Locations
- 🇺🇸
Alleghany Health Network, Pittsburgh, Pennsylvania, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸Baylor University, Dallas, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath